Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72

Ignacio Blanco, Ryuichi Kawatsu, Katherine Harrison, Peter Leichner, Samuel C. Augustine, Janina Baranowska-Kortylewicz, Margaret Tempero, David Colcher

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The immune response of 42 gastrointestinal and ovarian cancer patients at 1 month after exposure to murine monoclonal antibodies (B72.3 and CC49) reactive with the tumor associated antigen TAG-72 was studied. The incidence of human anti-mouse antibody response was 89% to B72.3 and 70% to CC49. To evaluate the antiidiotypic immune response, we developed a serological assay based on affinity chromatography to remove the interference due to the presence of TAG-72, antiisotypic, and antiallotypic immunoglobulins in the serum. Seventy-eight percent of patients who received B72.3 developed an antiidiotypic response; in 33% of the patients, this was the only immune response detected. The antiidiotypic immune response after treatment with CC49 was present in 54% of the patients. Twelve percent of the patients who received CC49 developed an antiidiotypic response in the absence of antiisotypic or antiallotypic immune response. The lower immunogenicity of the variable region of CC49 is encouraging when considering the use of chimeric or humanized antibodies derived from the murine monoclona1 antibody CC49 in clinical studies.

Original languageEnglish
Pages (from-to)96-106
Number of pages11
JournalJournal of Clinical Immunology
Volume17
Issue number1
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Monoclonal Antibodies
Antibodies, Monoclonal, Humanized
Gastrointestinal Neoplasms
Affinity Chromatography
Ovarian Neoplasms
Antibody Formation
Immunoglobulins
Anti-Idiotypic Antibodies
tumor-associated antigen 72
B72.3 antibody
Incidence
Serum
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. / Blanco, Ignacio; Kawatsu, Ryuichi; Harrison, Katherine; Leichner, Peter; Augustine, Samuel C.; Baranowska-Kortylewicz, Janina; Tempero, Margaret; Colcher, David.

In: Journal of Clinical Immunology, Vol. 17, No. 1, 1997, p. 96-106.

Research output: Contribution to journalArticle

Blanco, I, Kawatsu, R, Harrison, K, Leichner, P, Augustine, SC, Baranowska-Kortylewicz, J, Tempero, M & Colcher, D 1997, 'Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72', Journal of Clinical Immunology, vol. 17, no. 1, pp. 96-106. https://doi.org/10.1023/A:1027396714623
Blanco, Ignacio ; Kawatsu, Ryuichi ; Harrison, Katherine ; Leichner, Peter ; Augustine, Samuel C. ; Baranowska-Kortylewicz, Janina ; Tempero, Margaret ; Colcher, David. / Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. In: Journal of Clinical Immunology. 1997 ; Vol. 17, No. 1. pp. 96-106.
@article{1446c7fbebcf447fb0cb9d9643eafe49,
title = "Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72",
abstract = "The immune response of 42 gastrointestinal and ovarian cancer patients at 1 month after exposure to murine monoclonal antibodies (B72.3 and CC49) reactive with the tumor associated antigen TAG-72 was studied. The incidence of human anti-mouse antibody response was 89{\%} to B72.3 and 70{\%} to CC49. To evaluate the antiidiotypic immune response, we developed a serological assay based on affinity chromatography to remove the interference due to the presence of TAG-72, antiisotypic, and antiallotypic immunoglobulins in the serum. Seventy-eight percent of patients who received B72.3 developed an antiidiotypic response; in 33{\%} of the patients, this was the only immune response detected. The antiidiotypic immune response after treatment with CC49 was present in 54{\%} of the patients. Twelve percent of the patients who received CC49 developed an antiidiotypic response in the absence of antiisotypic or antiallotypic immune response. The lower immunogenicity of the variable region of CC49 is encouraging when considering the use of chimeric or humanized antibodies derived from the murine monoclona1 antibody CC49 in clinical studies.",
author = "Ignacio Blanco and Ryuichi Kawatsu and Katherine Harrison and Peter Leichner and Augustine, {Samuel C.} and Janina Baranowska-Kortylewicz and Margaret Tempero and David Colcher",
year = "1997",
doi = "10.1023/A:1027396714623",
language = "English",
volume = "17",
pages = "96--106",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Antiidioptypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72

AU - Blanco, Ignacio

AU - Kawatsu, Ryuichi

AU - Harrison, Katherine

AU - Leichner, Peter

AU - Augustine, Samuel C.

AU - Baranowska-Kortylewicz, Janina

AU - Tempero, Margaret

AU - Colcher, David

PY - 1997

Y1 - 1997

N2 - The immune response of 42 gastrointestinal and ovarian cancer patients at 1 month after exposure to murine monoclonal antibodies (B72.3 and CC49) reactive with the tumor associated antigen TAG-72 was studied. The incidence of human anti-mouse antibody response was 89% to B72.3 and 70% to CC49. To evaluate the antiidiotypic immune response, we developed a serological assay based on affinity chromatography to remove the interference due to the presence of TAG-72, antiisotypic, and antiallotypic immunoglobulins in the serum. Seventy-eight percent of patients who received B72.3 developed an antiidiotypic response; in 33% of the patients, this was the only immune response detected. The antiidiotypic immune response after treatment with CC49 was present in 54% of the patients. Twelve percent of the patients who received CC49 developed an antiidiotypic response in the absence of antiisotypic or antiallotypic immune response. The lower immunogenicity of the variable region of CC49 is encouraging when considering the use of chimeric or humanized antibodies derived from the murine monoclona1 antibody CC49 in clinical studies.

AB - The immune response of 42 gastrointestinal and ovarian cancer patients at 1 month after exposure to murine monoclonal antibodies (B72.3 and CC49) reactive with the tumor associated antigen TAG-72 was studied. The incidence of human anti-mouse antibody response was 89% to B72.3 and 70% to CC49. To evaluate the antiidiotypic immune response, we developed a serological assay based on affinity chromatography to remove the interference due to the presence of TAG-72, antiisotypic, and antiallotypic immunoglobulins in the serum. Seventy-eight percent of patients who received B72.3 developed an antiidiotypic response; in 33% of the patients, this was the only immune response detected. The antiidiotypic immune response after treatment with CC49 was present in 54% of the patients. Twelve percent of the patients who received CC49 developed an antiidiotypic response in the absence of antiisotypic or antiallotypic immune response. The lower immunogenicity of the variable region of CC49 is encouraging when considering the use of chimeric or humanized antibodies derived from the murine monoclona1 antibody CC49 in clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=0030614926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030614926&partnerID=8YFLogxK

U2 - 10.1023/A:1027396714623

DO - 10.1023/A:1027396714623

M3 - Article

VL - 17

SP - 96

EP - 106

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 1

ER -